Format

Send to:

Choose Destination
See comment in PubMed Commons below
Viruses. 2012 Dec 10;4(12):3589-605. doi: 10.3390/v4123589.

Development of live-attenuated influenza vaccines against outbreaks of H5N1 influenza.

Author information

  • 1Shanghai Institute of Biological Products, 1262 YanAn Road(w), 200052, Shanghai, China. daisy_zd@hotmail.com

Abstract

Several global outbreaks of highly pathogenic avian influenza (HPAI) H5N1 virus have increased the urgency of developing effective and safe vaccines against H5N1. Compared with H5N1 inactivated vaccines used widely, H5N1 live-attenuated influenza vaccines (LAIVs) have advantages in vaccine efficacy, dose-saving formula, long-lasting effect, ease of administration and some cross-protective immunity. Furthermore, H5N1 LAIVs induce both humoral and cellular immune responses, especially including improved IgA production at the mucosa. The current trend of H5N1 LAIVs development is toward cold-adapted, temperature-sensitive or replication-defective vaccines, and moreover, H5N1 LAIVs plus mucosal adjuvants are promising candidates. This review provides an update on the advantages and development of H5N1 live-attenuated influenza vaccines.

PMID:
23223214
[PubMed - indexed for MEDLINE]
PMCID:
PMC3528281
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
    Loading ...
    Write to the Help Desk